Abstract
After a decade of limited success in drug development for advanced biliary tract cancers, a wave of targeted therapeutics has become available for tumours with alterations in FGFR2, IDH1, BRAF, mismatch repair proteins, and NTRK.1 HER2 (also known as ERBB2) now joins this expanding list of molecular targets with the results of the HER2-positive biliary tract cancer cohort of the MyPathway basket study.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
